FDA Breakthrough: Kerendia (Finerenone) Cleared for Chronic Kidney Disease in Type 1 Diabetes

In a major milestone for endocrinology and nephrology, the U.S. Food and Drug Administration (FDA) has officially approved Bayer’s Kerendia (finerenone) for a vital new indication. Under this expansion, finerenone is now authorized for adult patients suffering from chronic kidney disease (CKD) associated with type 1 diabetes (T1D). This monumental decision introduces the first FDA-approved therapeutic treatment option specifically tailored for adults with type 1 diabetes-linked kidney disease in more than thirty years.

The primary clinical goal under this expanded indication is to reduce the urinary albumin-to-creatinine ratio (UACR) in this vulnerable patient group. Achieving a sustained reduction in UACR directly correlates with lowering the risk of a progressive decline in estimated glomerular filtration rate (eGFR) and halting progression toward end-stage kidney disease.

Addressing the Hidden Burden of Type 1 Diabetes-Associated CKD

Chronic kidney disease is a severe and frequent long-term microvascular complication for individuals managing type 1 diabetes. Bayer estimates that roughly 20% to 30% of all people living with type 1 diabetes in the United States develop CKD. These patients face heightened, life-threatening risks of rapid kidney function loss, complete renal failure, and severe cardiovascular complications.

Finerenone functions as a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA). By selectively blocking the harmful pathways triggered by the overactivation of mineralocorticoid receptors—which heavily drive both renal disease progression and cardiovascular tissue damage—finerenone provides targeted cellular protection.

Robust Clinical Evidence: The FINE-ONE Trial

The FDA’s regulatory green light was backed heavily by primary data from the landmark Phase III FINE-ONE trial, which investigated the safety and efficacy of finerenone in adults diagnosed with T1D-associated CKD.

Global Scope: The rigorous, randomized clinical study evaluated 242 participants across more than 80 specialized clinical sites spanning nine different countries. Participants were administered either once-daily finerenone or a placebo alongside standard-of-care management.
Significant UACR Redactions: After six continuous months of treatment, finerenone achieved a statistically significant 25% reduction in UACR from baseline compared to the placebo arm.
High Response Rate: Furthermore, 68.1% of study participants treated with finerenone achieved at least a 30% reduction in UACR at any point following baseline, compared to only 46.6% in the placebo group.

This data was further reinforced by pooled evidence from the previous Phase III FIDELIO-DKD and FIGARO-DKD trials involving patients with type 2 diabetes-associated CKD, where analyses showed that more than 80% of the observed renal benefits were directly explained by reductions in UACR. Furthermore, the safety profile observed during the FINE-ONE trial remained consistent with historical safety data, generating no new safety signals.

Expanding Clinical Horizons for Cardiovascular and Renal Care

This latest expansion builds upon finerenone’s established utility in the U.S. pharmaceutical landscape. Kerendia originally received FDA approval in 2021 to treat adult patients with CKD tied to type 2 diabetes, followed by a subsequent indication for specific heart failure patients with a left ventricular ejection fraction of at least 40%.

For the broader pharmaceutical industry, this landmark authorization highlights how surrogate biomarkers—such as UACR reductions—can successfully pave the way for accelerated, impactful drug development programs targeting progressive, hard-to-treat kidney conditions.